Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Disparities in access and practice patterns of BCMA-directed therapies in multiple myeloma

Shonali Midha, MD, Dana-Farber Cancer Institute, Boston, MA, discusses a study which used a global survey to analyze practice patterns for managing the side effects of BCMA-targeting immunotherapies, such as bispecific antibodies and CAR-T cells, in patients with multiple myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Pfizer, AbbVie